Researchers at the University of Pennsylvania also showed that the selective inhibition of the mTOR pathway benefits hepatic lipid metabolism and prevents the onset and progression of NAFLD (Gosis et al., 2022). Here, MTOR is linked to metabolic dysfunction-associated steatotic liver disease.